Lymphocyte infusion with lymphoma and leukemia immunotherapy
- Author:
- No author available
- Journal Title:
- JOURNAL OF LEUKEMIA & LYMPHOMA
- Issue:
- 5
- DOI:
- 10.3760/cma.j.issn.1009-9921.2010.05.001
- Key Word:
- 白血病;淋巴瘤;淋巴细胞输注;TCR转基因;母子嵌合状态;Leukemia;Lymphoma;Lymphocyte transfusion;TCR gene transfer;Child-maternal microchimerism
Abstract： Remarkable achievements have been made for lymphocyte infusion of lymphoma and leukemia, especially of lymphoproliferative disease within twenty-first century. The donor lymphocyte infusion or mobilized donor lymphocyte infusion (DLI/DSI) offer an opportunity of second remission for relapse patients post-transplantation. Cytokine-induced killer/DC cytokine-induced killer play an anti-tumor activity beyond non-MHC restricted. Cytotoxic lymphocyte infusion activated by synthetic tumor antigen produces targeted effects of anti-tumor. Transgenic CTL of anti-tumor TCR has brought the dawn in lymphoma and leukemia patients with defective lymphocytes. Maternal lymphocyte infusion play an anti-tumor/viral activity by avoiding the immune barrier of HLA mismatch.
- [1]张新,朱平,张蕊,等.用TCR β可变区基因阵列反映疾病的淋巴细胞克隆变化[J].2001,(6).
- [2]刘岩,顾江英,欧媛,等.白血病过继免疫治疗时外周血T淋巴细胞诱导培养后的克隆性变化[J].2009,(3).
- [3]王煜,牛洪泉,董芳永,等.树突状细胞疫苗免疫治疗策略[J].2005,(6).
- [4]童春容,耿彦彪,陆道培.自体细胞因子诱导的杀伤细胞治疗急性白血病的临床研究[J].2000,(5).
- [5]刘辉,朱平,林宁晶,等.构建免疫球蛋白与细胞因子融合基因表达载体的家族特异性抗淋巴瘤疫苗[J].2004,(1).
- [6]朱平.独特型疫苗治疗淋巴系统肿瘤的分子机理[J].1997,(4).
- [7]Gu JY,Liu J,Du JW,etc.TCR spectratyping revealed T lymphocytes associated with graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.[J].2007,48(8).
- [8]Toshihisa Komori,Haruo Sugiyama,Hiroyasu Ogawa,etc.Treatment of a Patient in a Relapse after Bone Marrow Transplantation for Acute Lymphoblastic Leukemia with the Systemic Administration of Allogeneic Lymphokine-Activated Killer Cells and Recombinant Interleukin-2[J].1989,43(2).
- [9]M A, Roskrow,N, Suzuki,Y j, Gan,etc.Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease.[J].1998,91.
- [10]Slobod KS,Pule M,Heslop HE.Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.[J].2010,115(5).
- [11]Drobyski WR,Verfaillie C,List A,etc.Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.[J].1997,15(2).
- [12]D. Phelan,G. Hadley,B. Duffy,etc.Antiidiotypic antibodies to HLA class I alloantibodies in normal individuals: A mechanism of tolerance to noninherited maternal HLA antigens[J].1991,31(1).
- [13]Raiola AM,Bregante S,Romagnani C,etc.Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions.[J].2003,31(8).
- [14]Straathof K,Rooney CM,Gee AP,etc.Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.[J].2009,113(11).
- [15]Chu B,Wang H,Zhu P,etc.An improved design of PCR primers for detection of human T cell receptor beta chain repertoire[J].2009,36(1).
- [16]Dotti G,Carbone A,Gloghini A.EBV-associated lymphoproliferative disorders: classification and treatment.[J].2008,13(5).
- [17]Soiffer RJ,Stein B,Ritz J,etc.Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia.[J].2000,106(5).
- [18]Uhlin,M.,Okas,M.,Gertow,J.,etc.A novel haplo-identical adoptive CTL therapy as a treatment for EBV-associated lymphoma after stem cell transplantation[J].2010,59(3).
- [19]Smits, J,Stevens, CE,van Rood, JJ,etc.Reexposure of cord blood to noninherited maternal HLA antigens improves transplant outcome in hematological malignancies[J].2009,106(47).
- [20]Crombez P,Martiat P,De Muynck H,etc.Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study.[J].2003,31(1).
- [21]Dudley ME,Rosenberg SA.Adoptive cell therapy for the treatment of patients with metastatic melanoma.[J].2009,21(2).